Magenta Therapeutics, Inc. - MGTA STOCK NEWS

Magenta Therapeutics has reported promising top-line results from an investigator-initiated Phase 2 clinical trial of MGTA-145 for stem cell mobilization in patients with multiple myeloma. The study involved 25 patients, with 88% successfully mobilizing 2 million CD34+ stem cells per kg. A poster presentation will occur at the 2021 American Society of Hematology Annual Meeting from December 11-14, 2021. Additionally, successful preclinical data for CD117 antibody drug conjugate in gene therapy models was shared, highlighting potential advances in stem cell transplantation regimens.

Magenta Therapeutics (NASDAQ: MGTA) has appointed Dr. Jeffrey Humphrey as Chief Medical Officer, overseeing clinical development and regulatory initiatives. Dr. Humphrey brings extensive experience, having led the development of over 20 drug candidates and driven multiple drug approvals in the U.S. and Europe. He previously served as CMO at Constellation Pharmaceuticals and held senior roles in notable companies like Bristol-Myers Squibb and Pfizer. His focus will be on advancing the company's clinical programs, including MGTA-145 and MGTA-117, aimed at enhancing stem cell transplant availability.

Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, at 4:40 p.m. ET. The event aims to showcase the company's innovative approaches in stem cell transplant therapies for patients with blood cancers and genetic diseases. A live webcast will be available on the Magenta website, with a replay accessible for 90 days post-event. For further details, please visit www.magentatx.com.

Magenta Therapeutics announced that its IND application for MGTA-117 has been activated by the FDA, paving the way for a Phase 1/2 clinical trial set to commence in Q4 2021. This trial targets patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The MGTA-117 is an antibody-drug conjugate designed to replace toxic conditioning agents, potentially broadening access to stem cell transplants. Collaborations with AVROBIO and Beam Therapeutics are planned to explore gene therapy applications.

Magenta Therapeutics (Nasdaq: MGTA) reported Q2 2021 financial results, revealing a net loss of $16.9 million, improved from $19.1 million in Q2 2020. As of June 30, 2021, the company holds $207.8 million in cash and marketable securities, expected to sustain operations into Q3 2023. Noteworthy developments include ongoing Phase 2 trials for MGTA-145 and plans for a Phase 1/2 trial for MGTA-117 following the resolution of a clinical hold by the FDA. The company aims to enhance stem cell transplant accessibility for patients with blood cancers and genetic disorders.

Magenta Therapeutics (Nasdaq: MGTA) announced its participation in two upcoming August investor conferences. The company will present at the BTIG Virtual Biotechnology Conference on August 9 at 12:00 p.m. ET and will also be featured in a panel discussion at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10 at 9:10 a.m. ET. Magenta focuses on developing stem cell transplant therapies for blood cancers, genetic, and autoimmune diseases. For further details, visit Magenta's website.

Magenta Therapeutics (Nasdaq: MGTA) announced a clinical hold from the FDA regarding its Phase 1/2 trial of MGTA-117 for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The hold requires an additional bioassay for dose escalation and safety monitoring. Magenta is developing this bioassay and expects to resolve the hold through an upcoming 'Type A' meeting with the FDA. The company ended Q2 2021 with over $200 million in cash, supporting its ongoing plans for MGTA-117's development.

Magenta Therapeutics (NASDAQ: MGTA) has appointed Caren Deardorf as its first Chief Commercial Officer. With over 25 years of international biotechnology experience, Deardorf aims to enhance Magenta’s global commercial strategies as the company progresses in developing treatments for blood cancers and genetic diseases. Previously, she was CCO at Ohana Biosciences and has held significant roles at Biogen, including leading the launch of SPINRAZA®, a therapy for spinal muscular atrophy. This new leadership is expected to aid Magenta in establishing its commercial capabilities as it enters a critical phase of product development.

Magenta Therapeutics (NASDAQ: MGTA) announced the appointment of Thomas Beetham as Chief Legal Officer, bringing over 20 years of experience in legal and business development from companies like Kiniksa Pharmaceuticals and Synageva BioPharma. He will lead Magenta's legal and compliance operations. CEO Jason Gardner emphasized the value of Beetham's expertise as the company advances its clinical pipeline aimed at making stem cell transplants more accessible for blood cancers and genetic diseases.